

**Experimental Study of the Effects of
Boswellia Serrata and Ginger (Zingiber
officinale) on Alzheimer's Disease
Induced in Rats**

**Thesis submitted for fulfillment of
Medical Doctorate degree in Medical Pharmacology**

By

Bassant Mohamed Mahmoud Ibrahim

M.Sc.

Under supervision of

Professor Dr.Nadia Aly Mohamed Gouda

Professor of Medical Pharmacology

Faculty of Medicine

Cairo University

Professor Dr.Abd El-Fattah Hassan Marrie

Professor and Chairman of Medical Pharmacology Department

Faculty of Medicine

Cairo University

Professor Dr.Nemat Ahmed Zakaria Yassin

Professor and Chairman of Pharmacology Department

Medical Division

National Research Centre

Professor Dr.Siham Mostafa Aly Elshenawy

Professor of Pharmacology

Medical Division

National Research Centre

2012

Acknowledgments

I wish to express my deepest gratitude to **Professor Dr.Nadia Aly Mohamed Gouda**, Professor of Medical Pharmacology, Faculty of Medicine, Cairo University, and **Professor Dr.Abd El-Fattah Hassan Marrie**, Professor and Chairman of Medical of Medical Pharmacology Department, Faculty of Medicine, Cairo University. My deepest gratitude to Professor **Dr.Nemat Ahmed Zakaria Yassin**, Professor and Chairman of Pharmacology Department, National Research Centre, and **Professor Dr.Siham ElShenawy**, Professor of Pharmacology, National Research Centre. My gratitude for all of them for their great effort throughout the whole work. I really deeply appreciate their great help and their valuable supervision.

I wish also to thank **Professor Dr. Karam Mahdy**, Professor of Chemistry, National Research Centre, for his help and guidance throughout this work.

Also my appreciation to Professor **Dr.Abdel-Razek**, Professor of Pathology, National Research Centre, for his effort in the pathologic studies.

Many thanks to all the staff working in the **Hormone Department**, National Research Centre, who performed the Biochemical tests on rat brain homogenate.

I wish to thank very much all my colleagues who helped me in preparing this work in its final form.

Bassant Mohamed

Abstract

Alzheimer's disease is now the most common cause of dementia. Increased oxidative stress, accumulation of oxidatively damaged nucleic acids, proteins, and lipids and inflammation induce deficits in cognitive and psychomotor performance and play an important role in development of Alzheimer's disease (AD). AD was induced in rats by giving AlCl_3 (17 mg / kg b.wt). Aqueous infusions of ginger (*Zingiber officinale*) (108 and 216 mg / kg b.wt), *Boswellia serrata* (45 and 90 mg / kg b.wt), rivastigmine (0.3 mg / kg b.wt) were given orally to study their protective as well as therapeutic effects on AlCl_3 induced AD in rats, which were evaluated by using behaviour stress tests as activity cage, rotarod and T-maze as well as by biochemical tests for detection of ACh and ACh E in brain homogenate and histopathologic examination.

Ginger and *Boswellia serrata* produced protective and therapeutic effects on AD.

Key words: Alzheimer's disease, oxidative, inflammation, cognitive, AlCl_3 , Ginger, *Boswellia serrata*, activity cage, rotarod, T-maze, ACh, Ach E.

Contents	
1.1. Introduction -----	1
1.2. Aim of work -----	3
<u>2. Review of literature:</u>	
2.1 Alzheimer's Disease: -----	4
2.1.1) Aetiology of Alzheimer's disease -----	4
2.1.2) Manifestations of Alzheimer's disease-----	7
2.1.3) Cholinergic hypothesis of Alzheimer's disease-----	8
2.1.4) Pathological changes in Alzheimer's disease-----	11
2.1.5) Treatment of Alzheimer's disease-----	12
2.1.5.1) Medical approach-----	13
2.1.5.1.1) Choline esterase inhibitors-----	13
2.1.5.1.1.A) First generation cholinesterase inhibitors-----	14
2.1.5.1.1.B) Second-generation cholinesterase inhibitors-----	15
2.1.5.1.2) Memantine-----	17
2.1.5.1.3) Secretase inhibitors-----	17
2.1.5.1.4) Brain derived neurotrophic factor (BDNF)-----	18
2.1.5.1.5) Melatonin-----	18
2.1.5.2) Clinically used herbal-originated drugs in AD treatment-----	18
2.1.5.2.1) Ginkgo biloba-----	18
2.1.5.2.2) Huperzine A -----	19
2.1.5.2.3) Alpha lipoic acid -----	19
2.1.5.2.4) Resveratrol -----	20
2.1.5.3) Immunization -----	20
2.2 Oxidative Stress -----	21
2.2.1) Antioxidant defensive mechanisms-----	22
2.2.2) Natural antioxidants-----	23

2.3 Ginger (<i>Zingiber officinale</i>)	24
2.3.1) Nutrient Composition	24
2.3.2) Phytochemistry	25
2.3.3) Traditional Use of Ginger	25
2.3.4) Pharmacological Effects	26
2.3.4.1) Anti-oxidant effect of Ginger	26
2.3.4.2) Anti-inflammatory activity	26
2.3.4.3) Effects on cardiovascular system	27
2.3.4.4) Anticoagulant/Antiplatelet potential	27
2.3.4.5) Cholesterol lowering effects	28
2.3.4.6) Hypoglycemic effect	28
2.3.4.7) Effects on the gastrointestinal tract	28
2.3.4.8) Antipyretic and Thermogenic effect	29
2.3.4.9) Antimicrobial effects	29
2.3.4.10) Effect on Nervous system	30
2.3.5) Safety of Ginger	30
2.4 Boswellia Serrata	31
2.4.1) Phytochemistry	31
2.4.2) Traditional use of Boswellia Serrata	32
2.4.3) Pharmacological Effects	32
2.4.3.1) Anti-inflammatory	32
2.4.3.2) Effect on nervous system	34
2.4.3.3) Anticancer effect of Boswellia Serrata	34
2.4.4) Mechanisms of Action	34
2.4.5) Safety of Boswellia serrata	35
2.5.1 Animal models of Alzheimer's Disease	36
2.5.1.1) Transgenic mouse model	36
2.5.1.2) Transgenic mice for both human A β and human α -synuclein	36
2.5.1.3) Doubly transgenic mice for human APP and human mutant tau	37

2.5.1.4) Acute cholinergic dysfunction-related animal models-----	37
2.5.1.5) Chronic animal model-----	37
2.5.2 Aluminium Chloride Toxicity-----	40
<i>Materials and methods</i> -----	42
<i>Results</i> -----	54
<i>Discussion & Conclusion</i> -----	124
<i>Summary</i> -----	147
<i>References</i> -----	150
الملخص العربي -----	192

LIST OF TABLES	PAGE
Table-1. Evaluation of protective effects of Ginger and Boswellia serrata aqueous infusions on AlCl₃ induced AD in rats by using Activity cage and Rotarod	60
Table-2. Evaluation of protective effects of Ginger and Boswellia serrata aqueous infusions on AlCl₃ induced AD in rats by using T-Maze.	67
Table-3. Effects of Ginger(108 and 216 mg/kg) and Boswellia serrata(45 and 90 mg/kg) aqueous infusions on Acetylcholine and Acetylcholine esterase levels in brain homogenate when used for protection from AlCl₃ induced AD in rats	71
Table-4. Evaluation of therapeutic effects of Ginger and Boswellia serrata aqueous infusions on AlCl₃ induced AD in rats by using Activity cage	76
Table-5. Evaluation of therapeutic effects of Ginger and Boswellia serrata aqueous infusions on AlCl₃ induced AD in rats by using Rotarod	84
Table-6. Evaluation of therapeutic effects of Ginger and Boswellia serrata aqueous infusions on AlCl₃ induced AD in rats by using T-Maze.	92
Table-7. Effects of Ginger (108 and 216mg/kg) and Boswellia serrata (45 and 90mg/kg) aqueous infusions on Acetylcholine and Acetylcholine esterase levels in brain homogenate when used for treatment of AlCl₃ induced AD in rats.	100
Table-8. Comparison of the effects of Ginger (108 and 216mg/kg) and Boswellia serrata (45 and 90mg/kg) aqueous infusions when used for protection and treatment of AlCl₃ induced AD in rats by using the Activity cage	105
Table-9. Comparison of the effects of Ginger (108 and 216mg/kg) and Boswellia serrata (45 and 90mg/kg) aqueous infusions when used for protection and treatment of AlCl₃ induced AD in rats by using the Rotarod	106
Table-10. Comparison of the effects of Ginger (108 and 216mg/kg) and Boswellia serrata (45 and 90mg/kg) aqueous infusions when used for protection and treatment of AlCl₃ induced AD in rats by using the T-Maze	107
Table-11. Comparison of the effects of Ginger (108 and 216mg/kg) and Boswellia serrata (45 and 90mg/kg) aqueous infusions on Acetylcholine and Acetylcholine esterase levels in brain homogenates when used for protection and treatment of AlCl₃ induced AD in rats.	108

List of Figures	page
Figure 1:Auguste Deter.	4
Figure 2:Schematic drawing of APP and generation of A β isoform .	6
Figure 3: Diagram of a neuron representing alterations in neurotransmission in AD.	9
Figure4: Ginger rhizome.	24
Figure 5: Boswellia Serrata (frankincense)	31
Figure 6: a) Activity cage b)Grid floor of activity cage	48
Figure 7: Rotarod .	50
Figure 8: T-Maze .	51
Figure 9: Protective effect of Ginger (108 and 216 mg/kg) aqueous infusion on AICl ₃ induced Alzheimer's disease in rats tested by using activity cage.	62
Figure 10: Protective effect of Boswellia serrata (45 and 90mg/kg) aqueous infusion on AICl ₃ induced Alzheimer's disease in rats tested by using activity cage.	62
Figure 11: Effect of Ginger(108 and 216mg/kg) aqueous infusion on protection from AICl ₃ induced Alzheimer's disease in rats tested by using rotarod.	63
Figure 12: Effect of Boswellia serrata(45 and 90 mg/kg) aqueous infusion on protection from AICl ₃ induced Alzheimer's disease in rats tested by using rotarod.	63
Figure 13:Effect of Ginger (108 and 216mg/kg) aqueous infusion on protection from AICl ₃ induced Alzheimer's disease in rats by usingT-Maze.	68
Figure 14:Effect of Boswellia serrata (45 and 90mg/kg) aqueous infusion on protection from AICl ₃ induced Alzheimer's disease in rats by usingT-Maze.	68
Figure 15:Effect of Ginger (108 and 216mg/kg)and Boswellia serrata(45 and 90mg/kg) aqueous infusion on Acetylcholine in brain homogenate when used for protection from AICl ₃ induced Alzheimer's disease in rats.	72
Figure 16:Effect of Ginger(108 and 216mg/kg) and Boswellia serrata(45 and 90mg/kg) aqueous infusions on Acetylcholine esterase in brain homogenate when used for protection from AICl ₃ induced Alzheimer's disease in rats.	72
Figure 17: The effect of Rivastigmine (0.3 mg/kg)on treatment of AICl ₃ induced Alzheimer's disease in rats by using the activity cage.	77
Figure 18: The effect of Ginger (108 mg/kg) aqueous infusion on treatment of AICl ₃ induced Alzheimer's disease in rats by using activity cage .	78
Figure 19: The effect of Ginger (216 mg/kg)aqueous infusion on treatment of AICl ₃ induced Alzheimer's disease in rats by using activity cage.	78
Figure 20: The effect of Boswellia Serrata(45 mg/kg)aqueous infusion on treatment of AICl ₃ induced Alzheimer's disease in rats by using the activity cage .	79
Figure 21: The effect of Boswellia Serrata(90 mg/kg)aqueous infusion on treatment of AICl ₃ induced Alzheimer's disease in rats by using the activity cage .	79
Figure 22: The Effect of Rivastigmine versus Ginger (108 and 216 mg/kg) and Boswellia Serrata (45 and 90 mg/kg)aqueous infusions given for 12 weeks for treatment of AICl ₃ induced Alzheimer's disease in rats by using the activity cage	80

List of Figures

Figure 23: The effect of Rivastigmine(0.3 mg/kg) on treatment of AlCl ₃ induced Alzheimer's disease in rats by using the rotarod	85
Figure 24: The effect of Ginger (108 mg/kg) aqueous infusion on treatment of AlCl ₃ induced Alzheimer's disease in rats by using the rotarod.	86
Figure 25: "The effect of ginger (216 mg/kg) aqueous infusion on treatment of AlCl ₃ induced Alzheimer's disease in rats by using the rotarod	86
Figure 26: The effect of Boswellia Serrata (45 mg/kg) aqueous infusion on treatment of AlCl ₃ induced Alzheimer's disease in rats by using the rotarod	87
Figure 27: The effect of Boswellia Serrata(90 mg/kg) aqueous infusion on treatment of AlCl ₃ induced Alzheimer's disease in rats by using the rotarod	87
Figure 28: Evaluation of the effect of Rivastigmine(0.3 mg/kg) versus Ginger(108 and 216 mg/kg) and Boswellia Serrata(45 and 90mg/kg) on treatment of AlCl ₃ induced Alzheimer's disease in rats by using the Rotarod	88
Figure 29: The effect of Rivastigmine(0.3 mg/kg) on treatment of AlCl ₃ induced Alzheimer's disease in rats by using the T-maze	93
Figure 30: Effect of Ginger (108 mg/kg) aqueous infusion on treatment of AlCl ₃ induced AD by using T-Maze test	93
Figure 31: Effect of Ginger (216 mg/kg) aqueous infusion on treatment of AlCl ₃ induced AD by using T-Maze test	94
Figure 32: Effect of Boswellia Serrata (45mg/kg) on treatment of AlCl ₃ induced Alzheimer's disease in rats by using the T-maze	94
Figure 33: Effect of Boswellia Serrata (90mg/kg) on treatment of AlCl ₃ induced Alzheimer's disease in rats by using the T-maze	95
Figure 34: Effect of Rivastigmine(0.3 mg/kg) versus Ginger (108 and 216mg/kg) and Boswellia Serrata(45 and 90mg/kg) on treatment of AlCl ₃ induced Alzheimer's disease in rats by using the T-maze	96
Figure 35: Effect of Ginger(108 and 216mg/kg) and Boswellia Serrata(45 and 90mg/kg) on Acetylcholine in brain homogenate when used for treatment of AlCl ₃ induced Alzheimer's disease in rats	101
Figure 36: Effect of Ginger(108 and 216mg/kg) and Boswellia Serrata(45 and 90mg/kg) on AchE in brain homogenate when used for treatment of AlCl ₃ induced Alzheimer's disease in rats	102
Figure 37: Section of brain of normal rat	111
Figure 38 a: Section of brain of positive control rat	111
Figure 38 b,c: Section of brain of positive control rat	112
Figure 39: Section of brain of rat receiving Rivastigmine 0.3mg/kg only for 15 days then Rivastigmine 0.3mg/kg + AlCl ₃ for four weeks used for protection from AD	113
Figure 40: Section of brain of rat receiving Ginger 108 mg/kg only for 15 days then Ginger 108 mg/kg + AlCl ₃ for four weeks used for protection from AD.	113
Figure 41: Section of brain of rat receiving Ginger 216 mg/kg only for 15 days then Ginger 216 mg / kg + AlCl ₃ for four weeks used for protection from AD.	114
Figure 42: Section of brain of rat receiving of Boswellia Serrata 45mg/kg only for 15 days then Boswellia Serrata 45 mg/kg + AlCl ₃ for four weeks used for protection from AD.	114

List of Figures

Figure 43: Section of brain of rat receiving Boswellia Serrata 45 mg / kg only for 15 days then Boswellia Serrata 90 mg / kg + AlCl ₃ for four weeks used for protection from AD.	115
Figure 44: Section of brain of rat receiving Boswellia Serrata 90 mg / kg only for 15 days then Boswellia Serrata 90 mg / kg + AlCl ₃ for four weeks used for protection from AD	115
Figure 45: Section of brain of normal rat (Therapeutic Study)	116
Figure 46 (a): Section (I) of brain (dissected after sixteen weeks of beginning of the experiment) of rat receiving Al Cl ₃ (17 mg/Kg) for four successive weeks and left without treatment of AD for twelve successive weeks	116
Figure 46 (b): Magnification of Fig 46	117
Figure 47: Section (II) of brain (dissected after sixteen weeks of beginning of the experiment) of rat receiving Al Cl ₃ (17 mg/Kg) for four successive weeks and left without treatment of AD for twelve successive weeks.	117
Figure 48: Section of brain of rat receiving Rivastigmine (0.3mg/kg) used for treatment of AD for twelve weeks after induction of AD by AlCl ₃	118
Figure 49: Section of brain of rat receiving Ginger 108 mg / kg used for treatment of AD for twelve weeks after induction of AD by AlCl ₃	118
Figure 50: Section of brain of rat receiving Ginger 216 mg / kg used for treatment of AD for twelve weeks after induction of AD by AlCl ₃	119
Figure 51: Section of brain of rat receiving Ginger 216 mg / kg used for treatment of AD for twelve weeks after induction of AD by AlCl ₃	119
Figure 52: Section (I) of brain of rat receiving Boswellia Serrata 45mg / kg used for treatment of AD for twelve weeks after induction of AD by AlCl ₃	120
Figure 53: Section (II) of brain of rat receiving Boswellia Serrata 45mg / kg used for treatment of AD for twelve weeks after induction of AD by AlCl ₃	120
Figure 54: Section of brain of rat receiving Boswellia Serrata 90 mg / kg used for treatment of AD for twelve weeks after induction of AD by AlCl ₃	121
Figure 55: Section of the stomach wall of normal control rat	122
Figure 56: Section of the stomach of rat receiving Ginger 108 mg / kg only for 15 days then Ginger 108 mg/kg +AlCl ₃ 17 mg / kg for four weeks	122
Figure 57 (a): Section of the stomach of rat receiving Ginger 216 mg/kg only for 15 days then Ginger 216 mg/kg +AlCl ₃ 17 mg/kg for one month	123
Figure 57 (b): Magnification of Fig 58	123

Abbreviations

A

Ach: Acetylcholine
AchE: Acetylcholine esterase
AKPA: Acetyl-11-keto- β -boswellic acid
ADL: Activities of daily living
ATPase: Adenosine triphosphatase
ALA: Alpha lipoic acid
Al: Aluminum
AlCl₃: Aluminum chloride
ANOVA :One-way analysis of variance
AD: Alzheimer's disease
APP: Amyloid precursor protein
AICD: Amyloid precursor protein intracellular domain

B

A β : Beta-amyloid peptide
BBA: Beta-boswellic acid
BSA :Bovine serum albumin
BDNF :Brain derived neurotropic factor
BuChE: Butyrylcholinesterase
BHA :Butylated hydroxyanisole
b.wt :Body weight
BSD: Boswellia 45 mg /kg
BLD :Boswellia 90 mg /kg

C

Ca²⁺: Calcium
ChAT :Choline acetyl transferase
ChE :Cholinesterase
ChEI :Cholinesterase inhibitors
CuZnSOD :Copper zinc Super Oxide Dismutase
CA3: Cornu Ammonis3 area of hippocampus proper
COX :Cyclooxygenase

D

DPPH :1,1-diphenyl-2-picrylhydrazyl
DMBA :7, 12-dimethylbenz anthracene
DNA :Deoxy ribonucleic acid

E

ELISA :Enzyme linked immunosorbent assay
E.S.R :Erythrocyte sedimentation rate
EAA :Excitatory amino acid
ERK :Extracellular signal-regulated kinases 1 and 2

F

FAO :Food and Agriculture Organization of the United Nations
FDA:Food and Drug Administration

G

GABA :Gamma amino butyric acid
GRAS :Generally Recognised as Safe
GBE :Ginkgo biloba extract
GSH-PX :Glutathione peroxidase
gm :Gram
GIT :Gastro intestinal tract
GSD:Ginger 108 mg /kg
GLD:Ginger 216 mg /kg

H

5-HETE :5-hydroxyeicosatetraenoic acid
H₂O₂:Hydrogen peroxide

I

iNOS :Inducible nitric oxide synthetase
IA :Incensole Acetate
IL :Interleukins
i.c.v:Intra-cerebroventricular

J

JNK :c-Jun N-terminal kinase

K

KBA :11-keto boswellic acid
Kg:Kilogram

L

LTB₄:Leukotriene B₄
LPS :Lipopolysaccarides
LDL: Low density lipoproteins

M

MDA: Malondialdehyde
Mepaco: Arab company for pharmaceutical and medicinal plants
MTP : Microtubule proteins
ml : Milliliter
mg : Milligram
mM: Millimolar
MMSE: Mini mental state examination
MAPKs: Mitogen-activated protein kinases

N

NF- κ B: Nuclear factor kappa B
NGF : Nerve growth factor
NFTs : Neurofibrillary tangles
NO : Nitric oxide
NMDA : N-methyl-D-aspartate
NSAID : Non steroidal antiinflammatory drugs

P

PD: Parkinson's disease
pmol : Picomole
PMN : Polymorpho nuclear leucocytes
PUFA : Polyunsaturated fatty acids
*p*H : Power of hydrogen
PGE2: Prostaglandin E2

R

RNS : Reactive nitrogen species
ROS : Reactive oxygen species
RO \cdot : Alkoxy radical
ROO \cdot : Peroxyl radical
rpm : Rotations per minute

S

NaCl: Sodium chloride
s APP : Soluble amyloid precursor protein
S.E : Standard error
O $_2$ \cdot^- : Superoxide anion
SOD : Super oxide dismutase

T

TPA :12-O-tetradecanoylphorbol-13-Acetate
TBARS: Thiobarbituric acid reactive substance
TRPV3:Transient receptor potential vanilloid3
Tris-HCl: 2-Amino-2-hydroxymethyl-1,3-propanediol hydrochloride
TNF- α :Tumour necrosis factor

V

V717F :Valine at residue 717 substituted by phenylalanine
VLDL :Very low density lipoproteins

W

WBCs: White blood cells
Wks:weeks
WHO :World Health Organisation

1.1) Introduction

1.1.1) Alzheimer's disease

Alzheimer's disease (AD), which represents one of the most economically costly diseases to society is a neurodegenerative disorder characterized by progressive degeneration of hippocampal and cortical neurons that leads to impairment of memory and cognitive ability. Impairment of short-term memory is usually the first clinical feature, whereas retrieval of distant memories is preserved relatively well into the course of the disease. When the condition progresses, additional cognitive abilities are impaired, as the ability to calculate, and use common objects and tools. The pathological hallmarks of AD are senile plaques, which are spherical accumulations of the protein β -amyloid accompanied by degenerating neuronal processes, and neurofibrillary tangles, composed of paired helical filaments and other proteins. This corresponds to the clinical features of marked impairment of memory and abstract reasoning, with preservation of vision and movement **(Ryoichi & Masuo, 2009)**.

The selective deficiency of acetylcholine in AD, has given rise to the "cholinergic hypothesis," which proposes that a deficiency of acetylcholine is critical in the genesis of the symptoms of AD **(Terry & Buccafusco, 2003)**. Therefore a major approach to the treatment of AD has involved attempts to augment the cholinergic function of the brain. This involves the use of inhibitors of acetyl cholinesterase as tacrine, donepezil, rivastigmine, and galantamine **(Lon et al, 2008)**. Also other hypotheses state that inflammation plays a key role in the pathogenesis of AD. In addition excessive reactive oxygen species (ROS) levels are implicated in the aetiology of AD **(Zhu et al, 2006)**.